Mitchell Blutt, MD, is a pioneer in the private healthcare sector, the first doctor to successfully transition from practicing clinical medicine to a role as a professional healthcare investor. Now serving as CEO of Consonance Capital in New York City, Mitchell Blutt, MD is involved in a number of health-related organizations, including the New York Academy of Medicine.
For 22 years, the New York Academy of Medicine has awarded the Rudin Glaucoma Prize to physicians and researchers who demonstrate excellence in studying glaucoma as evidenced by their high-level contributions to peer-reviewed scientific journals. For the 2017 calendar year, the academy chose Mary Kelly, PhD, of Oregon Health & Science University as its winner, recognizing her paper titled, “Induced Pluripotent Stem Cells Restore Function in a Human Cell Loss Model of Open-Angle Glaucoma.”
The groundbreaking research discussed in this article is the first to show that stem cells can be used to deal with the baseline biological causes of glaucoma. Standard treatment manages the symptoms, but the use of stem cells could potentially give doctors a way to reverse the condition instead.